CLOs on the Move

RealAge

www.realage.com

 
RealAge, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.realage.com
  • 5375 Mira Sorrento Pl Ste 250
    San Diego, CA USA 92121
  • Phone: 858.200.7171

Executives

Name Title Contact Details

Similar Companies

Cyclehaus

Our 50-minute Indoor Cycling class is a complete immersion into a high-intensity environment of energy and exercise. Our workouts are perfectly tailored to cutting edge playlists, and designed to be a retreat from everyday life. Each ride, physically and mentally stimulating, will challenge you to new heights.

Biological Dynamics

Biological Dynamics Inc. is an early stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Biological Dynamics was founded in 2008 by Raj Krishnan and David Charlot, Bioengineering PHD graduates from the University of California, San Diego (UCSD). Our vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs.

Zuchelli

Zuchelli is a Seaford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PHNS

PHNS provides comprehensive information technology and business process services to hospitals, healthcare providers and other businesses across the United States.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.